An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3% w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days.

Trial Profile

An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3% w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs Astodrimer (Primary)
  • Indications Herpes genitalis; Herpes simplex virus infections; HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2008 Status changed from in progress to completed, as reported by Starpharma.
    • 01 Feb 2008 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.
    • 26 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top